Get the Stockscreener App
0.9509
0.41%
0.0039
After Hours:
.95
-0.0009
-0.09%
I Mab Adr stock is traded at $0.9509, with a volume of 196.87K.
It is up +0.41% in the last 24 hours and down -19.42% over the past month.
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$0.947
Open:
$0.96
24h Volume:
196.87K
Relative Volume:
0.52
Market Cap:
$77.18M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
-0.2499
EPS:
-3.8057
Net Cash Flow:
$-167.78M
1W Performance:
-2.97%
1M Performance:
-19.42%
6M Performance:
-45.66%
1Y Performance:
-37.85%
1-Day Range:
$0.9301
$0.9691
1-Week Range:
$0.91
$1.00
52-Week Range:
$0.8989
$2.5362
I Mab Adr Stock (IMAB) Company Profile
Compare IMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
0.9509 | 77.18M | 3.91M | -206.53M | -167.78M | -3.8057 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-21 | Initiated | Siebert Williams Shank | Buy |
| Jun-02-21 | Initiated | Daiwa Securities | Buy |
| Mar-15-21 | Initiated | Needham | Buy |
| Mar-03-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-25-21 | Initiated | Piper Sandler | Overweight |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-20 | Initiated | China Renaissance | Buy |
| Feb-11-20 | Initiated | Jefferies | Buy |
View All
I Mab Adr Stock (IMAB) Latest News
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - MSN
I-Mab names Sean Fu as new CEO - Investing.com India
Invitation: Vallourec Q3 2024 Results ReleaseConference Call on Friday, November 15, 2024 - The Manila Times
I-Mab ADR (NASDAQ: IMAB) Stock: Investors Need To Know This - Stocks Register
Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register
If You Don’t Buy Hub Cyber Security Ltd (NASDAQ: HUBC) Now, You’ll Kick Yourself Later - Stocks Register
Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Still Pointing Upwards - Stocks Register
Is Veritone Inc’s (NASDAQ:VERI) Stock On The Decline? - Stocks Register
Cisco Systems, Inc. (NASDAQ: CSCO): What’s Next After The Stock Plunge? - Stocks Register
Should This Give Tandem Diabetes Care Inc (NASDAQ: TNDM) Investors Sleepless Nights? - Stocks Register
Kinross Gold Corp. (NYSE: KGC) Investors Should Be Worried About This. - Stocks Register
Where Do Analysts See Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Heading? - Stocks Register
Not A Good News For Keycorp (NYSE: KEY): The Stock Could Go Down -34.98 Percent More - Stocks Register
Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading - MSN
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
IMAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Company’s Banking Shares: Up -42.43% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
It makes sense and dollars to buy I-Mab ADR (IMAB) stock - SETE News
Ratio Revelations: I-Mab ADR (IMAB)’s Financial Metrics in the Spotlight - The Dwinnex
I-Mab ADR (IMAB) Stock: From Low to High in 52 Weeks - The InvestChronicle
IMAB’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com
I-Mab reveals Phase 1 data for lung cancer treatment - Investing.com
Federal Hill Taphouse & Kitchen abruptly closes - WPRI.com
I-Mab ADR (IMAB)’s stock price in review: A technical analysis - US Post News
There is no doubt that I-Mab ADR (IMAB) ticks all the boxes. - SETE News
Earnings call: I-MAB Biopharma discusses pipeline progress and financials - Investing.com India
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - PR Newswire
Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com India
I-Mab appoints new chairman and interim CEO - Investing.com
2024-07-15 | I-Mab Announces Leadership Transitions | NDAQ:IMAB | Press Release - Stockhouse Publishing
Financial Health Report: I-Mab ADR (IMAB)'s Ratios Tell a Tale – DWinneX - The Dwinnex
Teva Acquires Rights to Oncology Biosimilar Candidates - Yahoo News UK
It is Poised to be a Bull Market for I-Mab ADR (IMAB) – Sete News - SETE News
I-Mab names new Chief Medical Officer to enhance oncology pipeline - Investing.com India
I-Mab names new Chief Medical Officer to enhance oncology pipeline By Investing.com - Investing.com
I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks
Analysts review I-Mab ADR's rating – Knox Daily - Knox Daily
I-Mab and Bristol Myers team up for cancer drug trial By Investing.com - Investing.com
Watch this stock's price performance: I-Mab ADR (NASDAQ:IMAB) – US Post News - US Post News
I-Mab ADR Inc. (IMAB) Price Performance: A Technical Analysis Perspective - The InvestChronicle
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier - Yahoo Lifestyle UK
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks - Yahoo Lifestyle UK
Patent Law Changes Pose Threat to I-Mab Adr's Drug Candidate ProtectionTipRanks.com - TipRanks
I-Mab Finalizes Divestiture and Resolves ObligationsTipRanks.com - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature.com
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis - Nature.com
Market Brief: Will the December CPI Report Help Further Tame Inflation Fears? - Morningstar
I Mab Adr Stock (IMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):